• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病例报告:伴有……种系致病变异的骨外尤因肉瘤

Case report: Extraskeletal Ewing sarcoma with a germline pathogenic variant of .

作者信息

Kang Min-Chae, Kong Sun-Young, Park Sang-Yoon, Park Seog-Yun, Lee Eun-Gyeong, Yoo Chong Woo, Kim Yun Hwan, Kim Hyeji, Choi Wonyoung

机构信息

Division of Rare and Refractory Cancer, National Cancer Center, Goyang, Republic of Korea.

Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea.

出版信息

Front Oncol. 2024 Oct 8;14:1422605. doi: 10.3389/fonc.2024.1422605. eCollection 2024.

DOI:10.3389/fonc.2024.1422605
PMID:39439958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11493533/
Abstract

(BRG1) is a core unit of the SWI/SNF complex, regulating gene transcription through chromatin remodeling. Germline variants have been reported to be associated with various malignancies. Here, we report the first case of extraskeletal Ewing sarcoma in a young female patient with a germline pathogenic variant of (c.3546 + 1G>A), diagnosed with next generation sequencing (NGS). This alteration was also identified in her familial lineage, including her sister who was previously diagnosed with small cell carcinoma of the ovary, hypercalcemic type, a malignancy highly associated with mutations. Despite undergoing radical surgery and receiving systemic treatments including VeIP (vinblastine, ifosfamide, cisplatin), and VDC (vincristine, doxorubicin, cyclophosphamide) regimens, the patient succumbed to death due to disease progression. With the implementation of NGS, we anticipate that more cases with mutations will be diagnosed in the future. Further research is necessary to unveil therapeutic targets associated for this oncogenic alteration.

摘要

(BRG1)是SWI/SNF复合物的核心单元,通过染色质重塑调节基因转录。据报道,种系变异与多种恶性肿瘤有关。在此,我们报告了首例患有种系致病性变异(c.3546 + 1G>A)的年轻女性患者发生的骨外尤文肉瘤,该病例通过下一代测序(NGS)确诊。在她的家族谱系中也发现了这种改变,包括她的姐姐,她的姐姐之前被诊断为高钙血症型卵巢小细胞癌,这是一种与 突变高度相关的恶性肿瘤。尽管接受了根治性手术并接受了包括VeIP(长春碱、异环磷酰胺、顺铂)和VDC(长春新碱、阿霉素、环磷酰胺)方案在内的全身治疗,但患者因疾病进展而死亡。随着NGS的应用,我们预计未来将诊断出更多携带 突变的病例。有必要进行进一步研究以揭示与这种致癌改变相关的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48d3/11493533/4d7f3d3a90ae/fonc-14-1422605-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48d3/11493533/43dcd41613e2/fonc-14-1422605-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48d3/11493533/7a51b61338c5/fonc-14-1422605-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48d3/11493533/34b5064fd1d7/fonc-14-1422605-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48d3/11493533/4d7f3d3a90ae/fonc-14-1422605-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48d3/11493533/43dcd41613e2/fonc-14-1422605-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48d3/11493533/7a51b61338c5/fonc-14-1422605-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48d3/11493533/34b5064fd1d7/fonc-14-1422605-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48d3/11493533/4d7f3d3a90ae/fonc-14-1422605-g004.jpg

相似文献

1
Case report: Extraskeletal Ewing sarcoma with a germline pathogenic variant of .病例报告:伴有……种系致病变异的骨外尤因肉瘤
Front Oncol. 2024 Oct 8;14:1422605. doi: 10.3389/fonc.2024.1422605. eCollection 2024.
2
Multiple Somatic Mutations of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: A Case Report.卵巢高钙血症型小细胞癌中SMARCA4的多个体细胞突变:一例报告
Cureus. 2024 May 21;16(5):e60802. doi: 10.7759/cureus.60802. eCollection 2024 May.
3
Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.SWI/SNF复合物ATP酶SMARCA4/BRG1和SMARCA2/BRM的双重缺失对高钙血症型卵巢小细胞癌具有高度敏感性和特异性。
J Pathol. 2016 Feb;238(3):389-400. doi: 10.1002/path.4633. Epub 2015 Dec 21.
4
Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).卵巢高钙血症型小细胞癌(SCCOHT)中肿瘤抑制因子SMARCA4的缺失。
Rare Dis. 2014 Nov 3;2(1):e967148. doi: 10.4161/2167549X.2014.967148. eCollection 2014.
5
SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.SMARCA4 缺陷型未分化子宫肉瘤(子宫恶性横纹肌样瘤):一种与未分化癌不同的临床病理实体。
Mod Pathol. 2018 Sep;31(9):1442-1456. doi: 10.1038/s41379-018-0049-z. Epub 2018 Apr 26.
6
Rhabdoid Tumor Predisposition Syndrome横纹肌样瘤易感综合征
7
Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.胚系 SMARCA4 突变在卵巢小细胞癌、高钙血症型和 SMARCA4 缺陷型未分化子宫肉瘤中的作用:一个家族的临床特征及与大样本队列的比较。
Gynecol Oncol. 2020 Apr;157(1):106-114. doi: 10.1016/j.ygyno.2019.10.031. Epub 2020 Jan 15.
8
Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type.高钙血症型卵巢小细胞癌患者的种系SMARCA4突变
Orphanet J Rare Dis. 2015 Mar 15;10:32. doi: 10.1186/s13023-015-0247-4.
9
Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.卵巢高钙血症型小细胞癌中SMARCA2和SMARCA4表达的同时缺失。
Mod Pathol. 2016 Jan;29(1):60-6. doi: 10.1038/modpathol.2015.129. Epub 2015 Nov 13.
10
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.胚系和体细胞 SMARCA4 突变特征性表现为卵巢,高钙血症型小细胞癌。
Nat Genet. 2014 May;46(5):438-43. doi: 10.1038/ng.2931. Epub 2014 Mar 23.

本文引用的文献

1
Laparoscopic ovarian tissue collection for fertility preservation in children with malignancies: a multicentric experience.腹腔镜下采集卵巢组织用于恶性肿瘤患儿的生育力保存:一项多中心经验
Front Surg. 2024 Jan 23;11:1352698. doi: 10.3389/fsurg.2024.1352698. eCollection 2024.
2
The role of chromatin remodeler SMARCA4/BRG1 in brain cancers: a potential therapeutic target.染色质重塑因子 SMARCA4/BRG1 在脑癌中的作用:一个潜在的治疗靶点。
Oncogene. 2023 Jul;42(31):2363-2373. doi: 10.1038/s41388-023-02773-9. Epub 2023 Jul 11.
3
ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
ACMG SF v3.2 临床外显子组和基因组测序中报告次要发现的列表:美国医学遗传学与基因组学学会 (ACMG) 的政策声明。
Genet Med. 2023 Aug;25(8):100866. doi: 10.1016/j.gim.2023.100866. Epub 2023 Jun 22.
4
Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer.SMARCA4 种系致病变异与卵巢癌早发相关的其他癌症易感基因。
Cancer Med. 2023 Jul;12(14):15256-15260. doi: 10.1002/cam4.6214. Epub 2023 Jun 22.
5
Large Pelvic Mass in a Female Adolescent: Atypical Presentation and Successful Treatment of Extraskeletal Ewing Sarcoma.一名女性青少年的巨大盆腔肿物:骨外尤文肉瘤的非典型表现及成功治疗
Healthcare (Basel). 2023 May 10;11(10):1373. doi: 10.3390/healthcare11101373.
6
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.SMARCB1/SMARCA4 或 EZH2 改变的肿瘤中塔西美塞他的治疗作用:来自 NCI-COG 儿科MATCH APEC1621C 的结果。
J Natl Cancer Inst. 2023 Nov 8;115(11):1355-1363. doi: 10.1093/jnci/djad085.
7
Ewing and Ewing-like sarcomas: A morphological guide through genetically-defined entities.尤文氏和尤文样肉瘤:通过基因定义实体的形态学指南。
Pathol Int. 2023 Jan;73(1):12-26. doi: 10.1111/pin.13293. Epub 2022 Dec 9.
8
What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients.我们对0至10岁骨骼发育不成熟的尤因肉瘤患儿的生存情况了解多少?一项对60例患者进行的多中心10年随访研究。
Cancers (Basel). 2022 Mar 12;14(6):1456. doi: 10.3390/cancers14061456.
9
: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy.: 染色质重塑基因改变与癌症发生和治疗的关系。
Mol Cancer Ther. 2021 Dec;20(12):2341-2351. doi: 10.1158/1535-7163.MCT-21-0433. Epub 2021 Oct 12.
10
Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.骨肉瘤:ESMO-EURACAN-GENTURIS-ERN儿童癌症临床实践诊断、治疗及随访指南
Ann Oncol. 2021 Dec;32(12):1520-1536. doi: 10.1016/j.annonc.2021.08.1995. Epub 2021 Sep 6.